NCT00044356 is a Phase 2 clinical trial of Allovectin-7® in Melanoma, sponsored by Vical.

Who is sponsoring NCT00044356?

NCT00044356 is sponsored by Vical.

What drugs are being tested in NCT00044356?

Interventions in NCT00044356: Allovectin-7®.

What condition does NCT00044356 study?

NCT00044356 studies Melanoma, Metastatic Melanoma, Malignant Melanoma, Skin Cancer.

Is NCT00044356 still recruiting?

NCT00044356 is currently completed. Last updated 5 July 2011.

Last reviewed 2011-07-05 · How we verify

NCT00044356

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase II Study of High-Dose Allovectin-7® in Patients With Advanced Metastatic Melanoma

Completed Phase 2 Last updated 5 July 2011

What this trial tests

Phase 2 trial testing Allovectin-7® in Melanoma in 133 participants. Completed in 1 September 2004.

Timeline

1 February 2001

Primary endpoint
1 August 2004

1 September 2004

Quick facts

Lead sponsor	Vical
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	133
Start date	1 February 2001
Primary completion	1 August 2004
Estimated completion	1 September 2004
Sites	16 locations across United States

Drugs / interventions tested

Allovectin-7®

Conditions studied

Melanoma — all drugs for Melanoma →
Metastatic Melanoma — all drugs for Metastatic Melanoma →
Malignant Melanoma — all drugs for Malignant Melanoma →
Skin Cancer — all drugs for Skin Cancer →

Sponsor

Vical — full company profile →

Who can join

18 and older, any sex, with Melanoma or Metastatic Melanoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this clinical trial is to determine if Allovectin-7®, an experimental gene-based immunotherapy, can shrink melanoma tumors. The trial will also examine if this treatment can improve the time to disease progression.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Lipid-based nucleic acid therapeutics with in vivo efficacy.
Sufian MA, Ilies MA. · · 2023 · cited 13× · PMID 36180107 · DOI 10.1002/wnan.1856
Advances in molecular imaging and targeted therapeutics for lymph node metastasis in cancer: a comprehensive review.
Wu Y, Shang J, Zhang X, Li N. · · 2024 · cited 5× · PMID 39702277 · DOI 10.1186/s12951-024-02940-4
Genomic and molecular alterations associated with primary resistance to immune checkpoint inhibitors.
Malhotra J, De S, Nguyen K, Lee P, et al · · 2024 · cited 3× · PMID 39271499 · DOI 10.1007/s00262-024-03825-z
Immunotherapy in the management of melanoma: current status.
Alston D, Brewer JD. · · 2013 · cited 1× · PMID 27471683 · DOI 10.2147/itt.s30824

Verify or expand the search:

Other recruiting trials for Melanoma

Currently open trials in the same condition.

NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07224425 — A Study in People With Advanced Cancer (Solid Tumours) to Test Different Doses of BI 3810944 and to Find Out Whether it · Phase 1 · recruiting
NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
NCT07225036 — Promoting Immunotherapy Efficacy With Low-Dose Liver RT · NA · recruiting
NCT07379138 — Studying Quality of Life Inclusive of Mental Health and Cognitive Behavioral Therapy for Cancer Distress for the Improve · NA · recruiting

Other Vical trials

Trials by the same sponsor.

NCT03327727 — VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults · Phase 2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00044356 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vical
Last refreshed: 5 July 2011

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00044356.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing